CareCloud, Inc. (CCLD) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial guidance, AI product expansion, and strategic M&A plans, reflecting a positive outlook. The Q&A session supports this with positive feedback on AI products and a clear strategy for margin improvement and customer acquisition. Despite some vagueness in management responses, the overall sentiment is positive, indicating potential stock price appreciation.
Key Financial Performance
Revenue $31.3 million for Q1 2026, up 13% from $27.6 million in Q1 2025. The increase was driven by growth in recurring technology-enabled business solution revenue, which rose by approximately $5.3 million, offset by a $2.9 million decrease in non-recurring project-based professional services revenue from ASR.
GAAP Operating Income $1 million for Q1 2026, lower than the prior year's quarter. The decrease was primarily due to increased amortization of acquired intangible assets and integration costs associated with the Medsphere acquisition.
GAAP Net Income $922,000 for Q1 2026, compared to $1.9 million in Q1 2025. The decline was attributed to increased amortization of intangibles and transitional costs from the 2025 acquisitions.
Adjusted EBITDA $5.4 million for Q1 2026, or 17% of revenue, compared to $5.6 million in Q1 2025. The slight decrease was due to the integration of the Medsphere acquisition.
Free Cash Flow $2.4 million for Q1 2026, compared to $3.6 million in Q1 2025. The decrease was primarily due to the Medsphere integration.
Recurring Technology-Enabled Business Solution Revenue $23 million for Q1 2026, up approximately $5.3 million from Q1 2025. This growth was a key driver of the overall revenue increase.
Non-Recurring Project-Based Professional Services Revenue Decreased by approximately $2.9 million in Q1 2026 compared to Q1 2025, contributing to the overall revenue mix change.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AI Platform: Accelerating commercial traction with StratusAI Desk Agent, which automates 75% of inbound calls, and CirrusAI Notes for ambient documentation. AI-driven tools for prior authorization, medical coding, and clinical documentation are in development.
Medsphere Acquisition: Expanded product portfolio to include inpatient hospital market solutions like Wellsoft emergency department system, CareView inpatient EHR, and others.
Market Expansion: Entered the inpatient hospital market through Medsphere acquisition, significantly expanding addressable market.
AI Market: Targeting a $4 billion addressable market in the U.S. for AI Front Desk capabilities.
Operational Efficiency: AI applied internally to reduce claim errors, improve documentation accuracy, and increase first-pass acceptance rates. AI-driven tools are also enhancing software development processes.
Capital Structure Simplification: Replaced high-cost preferred dividends with lower-cost senior debt, simplifying the balance sheet and reducing the weighted average cost of capital.
AI Strategy: Pursuing a three-track AI strategy: internal cost optimization, embedding AI into existing products, and developing new AI products.
Cross-Selling: Actively cross-selling AI and RCM services to existing ambulatory clients and Medsphere's hospital customer base.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Profitability Impact: Lower GAAP operating and net income compared to the prior year due to increased amortization of acquired intangible assets and integration costs from the Medsphere acquisition.
Integration Challenges: Ongoing integration of 2025 acquisitions, including Medsphere, has led to increased transitional costs and duplicative expenses, impacting net income and free cash flow.
Capital Structure Complexity: Historical complexity in capital structure due to preferred equity overhang, though steps have been taken to simplify it with new credit facilities and redemption of Series B preferred stock.
Operational Efficiency: Efforts to consolidate overlapping systems from acquisitions and deploy AI for operational efficiency are ongoing, with potential risks in achieving expected margin improvements.
AI Product Scaling: Scaling of new AI products like stratusAI Front Desk Agent and cirrusAI Notes is in early stages, with risks in ensuring successful implementation and adoption by clients.
Economic and Geopolitical Risks: Potential risks from economic uncertainties, though the company notes limited exposure to tariffs, recessions, inflation, and geopolitical conflicts in the Middle East and Ukraine.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: The company reaffirms its 2026 revenue guidance of $128 million to $132 million.
Adjusted EBITDA Guidance for 2026: The company expects adjusted EBITDA of $29 million to $31 million for 2026.
GAAP Earnings Per Share (EPS) Guidance for 2026: The company projects GAAP EPS of $0.20 to $0.23 for 2026, representing over a 100% increase from 2025 EPS of $0.10.
AI Revenue Contribution: The company anticipates accelerating revenue contributions from its AI platform, particularly StratusAI, throughout 2026.
Cross-Sell Opportunities: The company expects meaningful ramp-up in cross-sell opportunities from its 2025 acquisitions during the second half of 2026.
Operational Efficiency and Margin Improvement: The company plans to deploy AI in its back-office operations and consolidate overlapping systems from 2025 acquisitions, expecting ongoing margin improvements through 2026 and into 2027.
AI Product Development: The company is actively developing new AI products, including AI prior authorization, AI-assisted medical coding, and additional clinical documentation capabilities, with plans to bring them to market in 2026.
AI Market Opportunity: The addressable market for the AI Front Desk capability alone is estimated to exceed $4 billion in the United States.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Preferred Dividends: The company is exchanging high-cost preferred dividends for lower-cost senior debt, simplifying the capital structure and improving shareholder economics.
ATM Equity Facility: An at-the-market (ATM) equity facility has been put in place as a flexible tool for potential future use, not as a primary financing method.
Series B Preferred Stock Redemption: The Board elected to redeem 100% of the outstanding Series B preferred stock, scheduled for May 15, funded by a new credit facility.
Series A Preferred Stock Conversion: Approximately 80% of the Series A preferred stock was converted in March of the previous year, reducing preferred equity overhang.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:In the in-house patient software segment, what is the company's strategy and focus?
A:The company is executing a value creation strategy with four parallel work streams: 1) Technical debt remediation and modernization, including transitioning platforms like Wellsoft and CareView to cloud-based SaaS platforms. 2) Developing new capabilities, such as integrating PracticeMatch with Marketware and building features like implant log tracking. 3) Cross-portfolio integration with the CareCloud suite, including connecting Wellsoft to CareCloud's RCM infrastructure. 4) AI infusion, such as integrating cirrusAI into Wellsoft workflows and embedding AI into Marketware for intelligent candidate recommendations.
Q:What feedback has the company received on its new AI products like stratusAI, Voice Audit, and Notes?
A:The company has received significant interest and traction from customers. They are focused on implementation and expansion, ensuring customers complete trials successfully and adopt more agents. There are no issues in finding interest or rolling out contracts.
Q:What is the company's perspective on the opportunity for AI prior authorization, AI-assisted medical coding, and additional clinical documentation?
A:For medical coding, the company is deploying it internally to refine the product and achieve accuracy before expanding to other clients. For prior authorizations, they are integrating with external clearinghouses and payers, completing testing, and selecting pilot customers. They see significant opportunities in specialties like orthopedics and neurosurgeries, as well as in the hospital space with Medsphere.
Q:Why did the company decide to redeem the Series B shares now?
A:The company cited three main reasons: 1) Improved operating performance and free cash flow, enabling a senior debt-funded redemption. 2) Attractive senior debt facility economics for the $50 million facility. 3) Eliminating the preferred dividend burden, freeing up cash flow for growth investments, M&A, and common shareholders. This move simplifies the equity structure and makes the investment more attractive to a broader base of investors.
Q:When would the company consider using the ATM (At-The-Market) offering?
A:The company would consider using the ATM in specific circumstances: 1) To fund attractive, accretive M&A transactions. 2) If the stock price allows for opportunistic de-risking of the balance sheet. 3) To support clear growth objectives with defined return profiles. The company maintains a conservative posture and views the ATM as a tool for optionality, not a general financing source.
Q:How does the company's AI capabilities compare to competitors, and what functionality is most helpful for the salesforce?
A:The company differentiates itself by offering fully embedded, integrated AI solutions within its ecosystem, unlike competitors who provide bolt-on solutions. The AI capabilities, such as stratusAI, provide clear ROI for healthcare providers by freeing up internal resources for higher-value activities. The salesforce focuses on solutions like stratusAI that demonstrate clear value and utility to customers.
Q:How does the company expect margins to improve throughout the year, and what factors contribute to this?
A:Margins are expected to improve as the company eliminates duplicative and transitional costs from the Medsphere acquisition, and as amortization of intangible assets decreases over time. Seasonal factors, such as lower revenue in Q1 due to deductibles, also impact margins. Free cash flow is expected to exceed $2 million per month, providing capital for reinvestment and growth.
Q:What are the terms of the new credit facility?
A:The terms of the new credit facility are detailed in the company's 8-K filing, which includes all related documents.
Q:How is the company approaching customer acquisition costs (CAC) and salesforce expansion?
A:The company's salesforce has tripled compared to the previous year and focuses on cross-selling within the existing customer base. The company is pursuing a two-pronged growth strategy: organic growth and acquisitive growth. They aim to acquire customer relationships at a lower cost (0.6x to 1x revenue) compared to the industry average (1.2x to 1.4x revenue).
Q:Review of Unclear Management Responses
A:The management avoided providing specific industry numbers for the opportunity in AI prior authorization and medical coding, stating they did not have the data available at the moment. Additionally, while discussing the ATM offering, the response was somewhat vague about the exact circumstances under which it would be used, emphasizing optionality rather than providing concrete examples.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI Front
AI platform
AI portfolio
AI track
AI value
Bank
Desk Agent
Front Desk
MAP App
Norm
RCM AI
Series stock
acceptance
capital structure
cirrusAI Notes
claim
client day
code
cost
engagement benchmarking
equity
framework
hospital
indicator
integration
investor
margin
outcome
point
practice engagement
product client
redemption
remainder
software
stratusAI
tariff
track AI
way
work
CCLD Transcript
CareCloud, Inc. (CCLD) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights strong financial guidance, AI product expansion, and strategic M&A plans, reflecting a positive outlook. The Q&A session supports this with positive feedback on AI products and a clear strategy for margin improvement and customer acquisition. Despite some vagueness in management responses, the overall sentiment is positive, indicating potential stock price appreciation.
CareCloud, Inc. (CCLD) Q4 2025 Earnings Call Transcript
Positive3-12
The earnings call highlights strong financial performance, with increased revenue guidance and improved cash flows. The strategic focus on AI and the successful integration of acquisitions indicate a promising future. Positive analyst sentiment in the Q&A, especially regarding AI monetization and market opportunities, supports a strong positive outlook. The company's strategic initiatives and robust financial metrics suggest a likely stock price increase exceeding 8%.
CareCloud, Inc. (CCLD) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlights strong financial performance with a 9% revenue increase, improved GAAP EPS, and increased adjusted EBITDA. AI initiatives and product development show promise, with successful acquisitions enhancing market reach. The company maintains strong guidance and is strategically positioned for growth. The Q&A section reflects confidence in strategy execution and future profitability. Overall, despite some economic uncertainties and integration risks, the positive financial metrics and strategic initiatives suggest a positive stock price movement in the short term.
CareCloud, Inc. (CCLD) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call summary reveals strong financial performance with positive GAAP EPS, increased adjusted EBITDA, and robust free cash flow. The company has a strategic focus on AI, enhancing product competitiveness and operational efficiency, which is positively received by customers. Despite a slight revenue decline due to a non-recurring item, the overall financial health is strong. The Q&A section supports the positive outlook with plans for growth through AI and M&A. Therefore, the stock price is likely to see a positive movement in the next two weeks.
CCLD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
